Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.53 |
| ▸ | PDE2A | O00408 | 7/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | LGMN | Q99538 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL625343 | 0.90 | TLR7 (0.50) | TLR7PDE2ANR1I2LGMNRAB9A | |
| SCHEMBL625382 | 0.87 | RAB9A (0.46) | TLR7PDE2ANR1I2RAB9ANPC1 | |
| SCHEMBL14894001 | 0.87 | NR1I2 (0.56) | TLR7PDE2ANR1I2LGMNRAB9A | |
| SCHEMBL15522936 | 0.84 | TLR7 (0.49) | TLR7PDE2ANR1I2RAB9AMEN1 | |
| SCHEMBL15011536 | 0.84 | TLR7 (0.51) | TLR7PDE2AMEN1KMT2AL3MBTL1 | |
| SCHEMBL625583 | 0.84 | ALDH1A1 (0.44) | RAB9AMEN1KMT2ANPC1L3MBTL1 | |
| SCHEMBL14893956 | 0.83 | TLR7 (0.48) | TLR7PDE2ANR1I2LGMNRAB9A | |
| SCHEMBL625186 | 0.82 | P2RX7 (0.46) | TLR7RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL626256 | 0.81 | TLR7 (0.43) | TLR7L3MBTL1ALDH1A1HTT | |
| SCHEMBL627425 | 0.80 | TLR7 (0.50) | TLR7PDE2ANR1I2LGMNMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156788-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140315940-A1 | MORPHINAN COMPOUNDS | CONCERT PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-8772500-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| EP-2603490-A1 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130131036-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013062966-A2 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2012019315-A1 | NOVEL TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131036-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | TLR7 1110/4885PDE2A 698/4885NR1I2 210/4885 |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | TLR7 1619/4885PDE2A 807/4885NR1I2 219/4885 |
| US-20140315940-A1 | MORPHINAN COMPOUNDS | OPRL1, OPRM1, OPRK1 | TLR7 270/4885PDE2A 3827/4885NR1I2 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.